The Breast Cancer beta 4 Integrin and Endothelial Human CLCA2 Mediate Lung Metastasis*

Mossaad Abdel-Ghany, Hung-Chi Cheng, Randolph C. Elble, and Bendicht U. PauliDagger

From the Cancer Biology Laboratories, Department of Molecular Medicine, Cornell University College of Veterinary Medicine, Ithaca, New York 14853

Received for publication, January 18, 2001, and in revised form, April 19, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Adhesion of blood-borne cancer cells to the endothelium is a critical determinant of organ-specific metastasis. Here we show that colonization of the lungs by human breast cancer cells is correlated with cell surface expression of the alpha 6beta 4 integrin and adhesion to human CLCA2 (hCLCA2), a Ca2+-sensitive chloride channel protein that is expressed on the endothelial cell luminal surface of pulmonary arteries, arterioles, and venules. Tumor cell adhesion to endothelial hCLCA2 is mediated by the beta 4 integrin, establishing for the first time a cell-cell adhesion property for this integrin that involves an entirely new adhesion partner. This adhesion is augmented by an increased surface expression of the alpha 6beta 4 integrin in breast cancer cells selected in vivo for enhanced lung colonization but abolished by the specific cleavage of the beta 4 integrin with matrilysin. beta 4 integrin/hCLCA2 adhesion-blocking antibodies directed against either of the two interacting adhesion molecules inhibit lung colonization, while overexpression of the beta 4 integrin in a model murine tumor cell line of modest lung colonization potential significantly increases the lung metastatic performance. Our data clearly show that the beta 4/hCLCA2 adhesion is critical for lung metastasis, yet expression of the beta 4 integrin in many benign breast tumors shows that this integrin is insufficient to bestow metastatic competence on cells that lack invasiveness and other established properties of metastatic cells.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Colonization of secondary organs by blood-borne cancer cells marks the final, usually fatal stage in a long, multistep cascade of tumor progression that is propelled by an array of acquired, cumulative, genetic abnormalities and promoting tissue microenvironmental cues (1-5). Increasing evidence suggests that tumor cell targeting of preferred, secondary organs for metastasis is mediated by distinct endothelial cell adhesion molecules (6-8). These molecules are expressed constitutively (organ-specifically) on the endothelial cell luminal surface of select vascular compartments (e.g. capillaries, arterioles, and/or venules) (7). By binding blood-borne cancer cells at high affinity, these molecules mediate vascular arrest of tumor cells under hydrodynamic conditions (6-9) and, as shown recently, promote intravascular growth to form tumor colonies at these secondary target sites (10, 11). Using a unique large vessel endothelial cell system, in which an organ-specific vascular phenotype can be induced by growing "neutral" bovine aortic endothelial cells on matrix extracts of that organ (12), a lung-specific endothelial cell adhesion molecule, termed Lu-ECAM-1 (lung-endothelial cell adhesion molecule-1) was isolated, purified, and cloned by our laboratory (13-15). Lu-ECAM-1 is the prototype of a newly discovered mammalian family of proteins (termed CLCAs, for Cl- channel proteins, Ca2+-activated) (13), which, similar to the cystic fibrosis transmembrane conductance regulator (16, 17), serve the dual function of mediating chloride conductance and cell-cell adhesion (16-18). Lu-ECAM-1 protein, like all other members of the CLCA family, is synthesized as an ~125-kDa precursor protein that, upon membrane incorporation, is rapidly processed into N-terminal 90-kDa and C-terminal 35-kDa components (15, 18). The 90-kDa polypeptide is responsible for the adhesion qualities of CLCAs, promoting the Ca2+-dependent adhesion of a variety of lung metastatic cancer cells but not cancer cells that metastasize to other organ sites (12-15).

In this report, hCLCA21 cloned from a lung cDNA library (19) is identified as the human counterpart of Lu-ECAM-1. We show that hCLCA2 is expressed by endothelia from different lung vascular compartments and that lung colonization of established human breast cancer cell lines is dependent upon the tumor cells' ability to interact with hCLCA2. Breast cancer cell adhesion to hCLCA2 is mediated by the beta 4 integrin, which is prominently expressed in breast cancer cells that are able to colonize the lungs upon tail vein injection of nude mice (20). Cell-to-cell adhesion assays, adhesion-blocking assays with antibodies generated against either of the two interacting molecules, and overexpression of beta 4 in a murine model tumor cell line are used to confirm involvement of the beta 4 integrin/hCLCA2 adhesion mechanism in lung metastasis. Together, our data confirm that the alpha 6beta 4 integrin is a lung metastasis-associated gene (21) and establish for the first time a cell-to-cell adhesion property for the beta 4 integrin that involves an entirely new integrin adhesion partner.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Antibodies and Reagents-- Anti-Lu-ECAM-1 mAb 6D3 was produced in BALB/c mice (22) and selected for adhesion blocking of B16-F10 melanoma cells to Lu-ECAM-1-expressing bovine aortic endothelial cells (13, 14). Rabbit polyclonal antibodies (pAbs) 4 and 18 were generated against the hCLCA2 peptides KANNNSKIKQESYEKANV (amino acids 94-111) and ESTGENVKPHHQLKNTVTVD (amino acids 498-517), respectively. Antibodies against the beta 4 integrin ectodomain included mouse mAb 3E1 (Life Technologies, Inc.), rabbit pAb H101 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), and rabbit pAb 81435 directed against TA3/HA mouse mammary carcinoma cells (Dr. E. Roos, The Netherlands Cancer Institute, Amsterdam) (23). Rat anti-human alpha 6 integrin mAb GoH3 was from PharMingen (San Diego, CA), mouse anti-human beta 1 mAb 2253 from Chemicon (Temecula, CA), and mouse anti-human Myc mAb 9E10 and anti-phosphotyrosine mAb from Calbiochem. Human placental and murine EHS laminins as well as all other reagents were from Sigma.

Cell Cultures-- Human breast cancer cell lines MDA-MB-231, -435, -468, and -453 and MCF7 were from the ATCC (Manassas, VA). MDA-MB-435L2 was from Dr. J. E. Price (The University of Texas M.D. Anderson Cancer Center, Houston, TX) (20), and MDA-MB-435 transfected with wild type human beta 4 integrin or tailless beta 4 integrin (beta 4Delta cyt) were from Dr. A. M. Mercurio (Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA) (24). Human lung microvascular endothelial cells (HMVEC-L) and human aortic endothelial cells (HAEC) were from Clonetics (San Diego, CA). Human umbilical vein endothelial cells (HUVEC), human embryonic kidney 293 cells (HEK293), and Kirsten Ras-transformed Balb/3T3 (K-Balb/3T3) cells were from the ATCC. HMVEC-L were grown in EGM-2-MV BulletKit medium (Clonetics), and all others were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (Life Technologies).

RT-PCR Analyses-- Total RNA isolated from HMVEC-L, HAEC, and HUVEC was reverse-transcribed, and an 800-base pair hCLCA2 product amplified by PCR, using ttctctacaacatgacccaaaggagc and catgggaaagctgtggtgaaag as 5' and 3' primers, respectively, and Taq polymerase (Life Technologies) (19). The full-length 2.9-kilobase pair open reading frame of hCLCA2 was amplified from HMVEC-L RNA, using primers corresponding to the 5' (ttctctacaacatgacccaaaggagc) and 3' (gacactttggatatttatttataataattttgttc) ends of the hCLCA2 open reading frame. Both primer sets were tested on cloned plasmid templates to ascertain that they would not recognize other CLCA homologs. RNA extracted from HEK293 cells and processed in parallel served as negative control.

Expression, Myc Tagging, Immunoprecipitation, and Purification of hCLCA2-- Lung expression of hCLCA2 was analyzed by staining sections of paraffin-embedded, formaldehyde (4%)-fixed tissue with rabbit anti-hCLCA2 antiserum (pAb 4) at a 1:100 dilution (13, 22). Preimmune serum used at the same dilution served as control. Myc-tagged hCLCA2 constructs were generated as described and transfected into 80% confluent HEK293 using the LipofectAMINETM Plus protocol (Life Technologies) (19). Immunoprecipitated and immunopurified hCLCA2 were from extracts of transfected HEK293 cells (48 h after transfection), using anti-Myc mAb 9E10-conjugated goat anti-mouse IgG Dynabeads (or Protein G beads). Surface expression of hCLCA2 was confirmed by cell surface biotinylation (100 µg/ml Biotin N-hydroxysuccinimide) (25). Western blot analyses were done with anti-Myc mAb 9E10 (19).

Isolation, Purification, and Phosphorylation of the beta 4 Integrin Ligand of hCLCA2-- The tumor cell ligand of hCLCA2 was isolated from lysates of surface-biotinylated MDA-MB-231 breast cancer cells bound to a monolayer of transiently transfected Myc-hCLCA2-HEK293 cells by co-immunoprecipitation with anti-Myc mAb 9E10. In brief, MDA-MB-231 cells (5 × 104 tumor cells/cm2 of HEK293 monolayer surface) were allowed to adhere to Myc-hCLCA2-HEK293 monolayers (or control vector-transfected HEK293 monolayers) during a 20-min incubation period. After removing unbound tumor cells by washing, bound tumor cells and HEK293 cells were extracted in lysis buffer (26, 27), and extracts were subjected to immunoprecipitation with anti-Myc mAb 9E10. Immunoprecipitates were resolved by SDS-PAGE (6% polyacrylamide), blotted to nitrocellulose, and probed with streptavidin-HRP or anti-beta 4 mAb 3E1 followed by HRP-conjugated secondary antibody. Alternatively, the hCLCA2 tumor cell ligand was isolated by affinity chromatography from surface-biotinylated MDA-MB-231 cells using Myc-hCLCA2-conjugated anti-Myc mAb 9E10/goat anti-mouse IgG Dynabeads. Beads were boiled in SDS-sample buffer, and proteins were resolved by SDS-PAGE and blotted to nitrocellulose. Blots were probed with streptavidin-HRP, anti-beta 4 mAb 3E1, or anti-Myc mAb 9E10. Purification of beta 4 was accomplished with anti-beta 4 mAb 3E1-conjugated Protein G beads from lysates of MDA-MB-231 cells (108 cells/preparation). To further corroborate the specificity of the beta 4/hCLCA2 adhesion, MDA-MB-231 cancer cells were labeled with H332PO4 (0.5 mCi/ml) in phosphate-free DMEM for 4 h at 37 °C and then seeded onto BSA-, fibronectin-, hCLCA2-, laminin-, and poly-L-lysine-coated dishes and incubated for 20 min at 37 °C. Cell lysates were immunoprecipitated with anti-beta 4 mAb 3E1, and precipitates were resolved by SDS-PAGE, treated with 1 M KOH for 2 h at 55 °C, and autoradiographed to visualize beta 4 integrin tyrosine phosphorylation (28).

Gel Overlay (Far Western)-- beta 4 (immunopurified from MDA-MB-231), beta 1 (alpha 5beta 1), and beta 3 (alpha vbeta 3) (both from Chemicon) integrins were resolved by SDS-PAGE, blotted to nitrocellulose, denatured with 2.5 M guanidine, and renatured in 5% milk in Tris-buffered saline containing 0.1% Tween 20 (29). Blots were incubated with Myc-tagged hCLCA2 (overnight; 4 °C), and bound hCLCA2 was detected with anti-Myc mAb 9E10, followed by HRP-conjugated secondary antibody. Controls included blots probed with antibody alone. Positions on the gel and loading quantities of the beta  integrins were determined in parallel Western blots.

Transfection of K-Balb/3T3 Cells with beta 4 cDNA-- Wild-type beta 4 cDNA cloned into the expression vector pRC-CMV was from Dr. F. G. Giancotti. K-Balb/3T3 cells at 70% confluence were stably transfected with beta 4 cDNA by electroporation and selected for G418 resistance. Controls were K-Balb/3T3 cells transfected with vector alone. Cells were used for (a) FACS to quantify beta 4 surface expression (25), (b) adhesion to immunopurified mCLCA1 (14), and (c) lung colony assays (12-14).

FACS Analyses, Adhesion, and Lung Colony Assays-- FACS analyses, adhesion assays, and lung colony assays were performed as previously described in detail by our laboratory (12-14, 25).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

hCLCA2 Expression by Endothelia of the Lung Vasculature-- Human CLCA2 was cloned from a human lung cDNA library, and its amino acid sequence, protein processing, transmembrane topography, and channel properties are described elsewhere (19). Northern blot hybridization and/or RT-PCR revealed epithelial expression of hCLCA2 in the mammary gland and trachea (19), while RT-PCR and immunohistochemistry demonstrated endothelial cell expression in the lungs (Fig. 1). In the latter, hCLCA2 protein was expressed selectively in endothelia of small pulmonary arteries, arterioles, and subpleural and interlobular venules (Fig. 1, A-F), while endothelia in other tissues including brain, liver, pancreas, kidney, alimentary tract, testis, ovary, adrenal gland, thyroid, and skeletal muscle were negative (data not shown). Strong hCLCA2 expression was also observed in cultured HMVEC-L lung microvascular endothelial cells, while a weak hCLCA2 expression was recorded for endothelial cells derived from human aorta (HAEC) and umbilical vein (HUVEC) (Fig. 1G). Expression of hCLCA2 protein in HMVEC-L was confirmed by FACS, using the same polyclonal antibody that had been employed in the immunohistochemical studies (Fig. 1H).


View larger version (78K):
[in this window]
[in a new window]
 
Fig. 1.   Endothelial cell expression of hCLCA2. A-F, sections (2 µm thick) from paraffin-embedded, formaldehyde-fixed lung tissue blocks were stained with rabbit anti-hCLCA2 pAb 4 at a dilution of 1:100 (A, C, and E) or rabbit preimmune IgG (B, D, and F). Bound antibody was detected by HRP-conjugated goat anti-rabbit IgG antibodies and diaminobenzidine as substrate. A positive staining reaction is observed in small arteries (A), arterioles (C), and venules of interlobular septa (E). Comparable vessels stained with preimmune serum are negative (B, D, F). Bar, 100 µm. G and H, expression of hCLCA2 in cultured endothelial cells is shown by RT-PCR amplification of an 800-base pair hCLCA2 product from total RNA of HMVEC-L (lane 1), HAEC (lane 2), and HUVEC (lane 3) but not HEK293 (lane 4) (see "Experimental Procedures") and of the full-length 2.9-kilobase pair hCLCA2 open reading frame from HMVEC-L RNA (G) and by FACS analysis of HMVEC-L stained with rabbit anti-hCLCA2 pAb 4 (open histogram) or rabbit preimmune IgG (closed histogram) and fluorescein isothiocyanate-conjugated goat anti-rabbit IgG (H).

hCLCA2 Mediates Adhesion of Human Breast Cancer Cells via the beta 4 Integrin-- The selective expression of hCLCA2 on endothelia of lung blood vessels, which recently were implicated with location of tumor cell arrest and early intravascular micrometastasis formation by in situ epifluorescence microscopy (11), suggested that hCLCA2 could serve as the human counterpart of Lu-ECAM-1 and might play a major role in lung metastasis of blood-borne human cancer cells. To test this hypothesis, we selected three human breast cancer cells with different biological behaviors for adhesion to recombinant Myc-tagged hCLCA2 immunopurified from transfected HEK293 cells. The first cell line was MDA-MB-231, which efficiently colonizes the lungs of nude mice following tumor formation from cancer cells injected into mammary fat pads (orthotopic tumor xenografts) or intravenous injection; the second cell line was MDA-MB-435, which only forms lung metastases from orthotopic tumor xenografts but not after intravenous injection; and the third cell line was MCF7, which is nonmetastatic by either of the two modalities (20). Consistent with the proposed role of hCLCA2 in lung metastasis, only MDA-MB-231 cells adhered in strong numbers to recombinant hCLCA2 (Fig. 2A). Adhesion correlated with the amount of Myc-tagged hCLCA2 protein present in elution fractions from anti-Myc mAb 9E10 immunoaffinity columns and was dependent upon serum activation of tumor cells (Fig. 2B). To identify the tumor cell molecule that served as the ligand for hCLCA2, surface-biotinylated MDA-MB-231 cancer cells were allowed to bind to confluent monolayers of Myc-tagged hCLCA2- or vector-transfected HEK293 cells, yielding tumor cell adhesion values of ~75% for Myc-hCLCA2-HEK293 monolayers and 25% for vector-transfected HEK293 monolayers. Myc-hCLCA2-HEK293 monolayers were extracted together with bound tumor cells, and extracts were subjected to immunoprecipitation with anti-Myc mAb 9E10. Precipitated proteins resolved by SDS-PAGE and blotted to nitrocellulose were then probed with streptavidin-HRP. A single band of molecular size 205 kDa was identified that by Western analysis with anti-beta 4 mAb 3E1 was shown to be beta 4 integrin (Fig. 2C). Subsequent immunoprecipitation of Myc-hCLCA2-HEK293/MDA-MB-231 cell extracts with anti-beta 4 pAb H101 and Western probing of the precipitate with anti-Myc mAb 9E10 identified hCLCA2, further confirming the beta 4 integrin/hCLCA2 adhesion (Fig. 2D). Controls conducted with MDA-MB-231 cancer cells bound unspecifically to vector-transfected HEK293 monolayers did not yield any precipitate. Expansion of our initial hCLCA2/tumor cell adhesion studies to MDA-MB-435L2, MDA-MB-468, and MDA-MB-453 breast cancer cell lines supported the close correlation between surface expression of the beta 4 integrin, hCLCA2 adhesion, and lung colonization (Fig. 3, A-D). For example, the consistently high lung colonization potential of the MDA-MB-231 cell line correlated with high levels of beta 4 integrin expression and hCLCA2 adhesion, while modest lung colonization of the MDA-MB-435L2 cell line was associated with modest beta 4 expression and hCLCA2 adhesion (Fig. 3, A-D). All other breast cancer cell lines were unable to form lung colonies and, with the exception of the MDA-MB-468 cell line, expressed low or nondetectable levels of the beta 4 integrin and adhered poorly to hCLCA2 (Fig. 3, A-D). In the metastatically incompetent MDA-MB-468 cell line, an intermediate level of beta 4 expression correlated with a well differentiated, near normal cellular phenotype in vitro and slow adenomatous growth in vivo, implying that the MDA-MB-468 cell line represents an early stage in tumor progression.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 2.   The beta 4 integrin mediates adhesion of breast cancer cells to endothelial hCLCA2. A, adhesion of MDA-MB-231, MDA-MB-435, and MCF7 human breast cancer cells to hCLCA2 was tested in microtitration plates coated with ~3 µg/ml recombinant hCLCA2 (overnight; 4 °C). B, adhesion of MDA-MB-231 cells to Myc-tagged hCLCA2 from successive elution fractions of an anti-Myc mAb 9E10-immunoaffinity column. Protein G beads conjugated with anti-Myc mAb 9E10 were incubated with extracts from HEK293 cells transfected with Myc-tagged hCLCA2 (overnight; 4 °C), and bound protein was eluted with 200 mM glycine (pH 2.8) in 150 mM NaCl and 0.5% octyl-beta -glucoside. Elutes were collected in 1-ml fractions in 0.1 volume of 1 M Tris (pH 11) to yield a final pH of 8.2. Each fraction was evaluated for MDA-MB-231 adhesion and protein content by Western blotting with anti-Myc mAb 9E10. Adhesion values correlate well with the amount of hCLCA2 protein in the column fraction. C, surface-biotinylated or untreated MDA-MB-231 cells bound to HEK293 cell monolayers transfected with Myc-hCLCA2 (lanes 1) or HEK293 cell monolayers transfected with vector alone (lanes 2) (see "Experimental Procedures") were extracted in lysis buffer containing 5 mM EGTA. Extracts were subjected to immunoprecipitation with anti-Myc mAb 9E10, and SDS-PAGE-resolved and blotted precipitates were probed with streptavidin-HRP (left panel), anti-beta 4 mAb 3E1 (middle panel), or anti-Myc mAb 9E10 (right panel). D, anti-beta 4 pAb H101 immunoprecipitate from extracts of MDA-MB-231 bound to Myc-tagged hCLCA2-transfected (lanes 1) or vector-transfected (lane 2) HEK293 monolayers were probed by Western blot with anti-Myc mAb 9E10 (left panel) or anti-beta 4 mAb 3E1 (right panel).


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 3.   The beta 4 integrin expression correlates with hCLCA2 adhesion and lung colonization: FACS analyses of MDA-MB-231 (A), MDA-MB-435 (435) and MDA-MB-435L2 (435L2) (B), MDA-MB-468 (C), and MCF7 (D). Tumor cells were stained with either mouse anti-beta 4 mAb 3E1 (open histogram) or mouse IgG (gray filled histogram) and fluorescein isothiocyanate-conjugated goat-anti mouse IgG secondary antibody and then subjected to FACS analyses. The percentage of tumor cell adhesion to hCLCA2-coated dishes (3 µg/ml) and the number of lung colonies formed by each breast cancer cell line are displayed as insets.

Since isolation of the beta 4 integrin-hCLCA2 complex from MDA-MB-231/Myc-hCLCA2-HEK293 extracts and hCLCA2 affinity purification of the beta 4 integrin from MDA-MB-231 extracts (data not shown) were unable to rule out participation of an unknown, intermediary molecule in the binding of hCLCA2 to beta 4 integrin, the beta 4/hCLCA2 partnership was further examined by Far Western analysis. To accomplish this, adhesion receptor and ligand were first immunopurified from hCLCA2-transfected HEK293 cells and MDA-MB-231 cells, respectively, and their purity was assessed by SDS-PAGE and silver staining. After subjecting the SDS-PAGE resolved, blotted beta 4 integrin to cycles of denaturing and renaturing, blots were probed with Myc-tagged hCLCA2, and hCLCA2-binding to beta 4 was visualized by anti-Myc antibodies. hCLCA2 strongly and specifically bound to beta 4 integrin, but not to the control beta  integrin subunits beta 1 and beta 3 (Fig. 4A, lanes 1, 3, and 5). Control blots incubated with anti-Myc antibody alone were negative (Fig. 4A, lanes 2, 4, and 6). Western blotting (Fig. 4A, lanes marked W) confirmed positions and equal loading amounts of the three beta  integrins. To further scrutinize the specificity of the beta 4/hCLCA2 adhesion, Far Western analyses were also conducted with blot-immobilized hCLCA2 (Fig. 4B, lane W) that was probed with soluble beta 4 integrin immunopurified from MDA-MB-231 cell extracts. Binding of the beta 4 integrin to hCLCA2 was confirmed by staining with anti-beta 4 pAb H101 (Fig. 4B, lane 1), while blots that were stained with antibody alone in the absence of beta 4 integrin were negative (Fig. 4B, lane 2).


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 4.   Documentation of the beta 4 integrin/hCLCA2 adhesion by far Western analysis. Immunopurified integrins beta 4 (alpha 6beta 4), beta 1 (alpha 5beta 1), and beta 3 (alpha vbeta 3) (A) and hCLCA2 (B) were resolved by SDS-PAGE and blotted to nitrocellulose and then probed immediately with the respective anti-beta integrin antibodies (A) or anti-Myc mAb 9E10 (B) to confirm equal protein loading (W). After successive denaturing and renaturing cycles (29), parallel blots were incubated with immunopurified Myc-hCLCA2 (lanes 1, 3, and 5) or 1% BSA (lanes 2, 4, and 6) (A) or with immunopurified beta 4 integrin (lane 1) or 1% BSA (lane 2) (B) and probed with anti-Myc mAb 9E10 (A) or anti-beta 4 pAb H101 (B), respectively. In A only the beta 4 integrin is able to bind Myc-hCLCA2 (lane 1). Note that the beta 4 used in this study appears as a triplet of 205, 180, and 150 kDa (W), since it has been extracted from MDA-MB-231 cells in lysis buffer in the absence of 5 mM EGTA (26, 27). In B, immobilized hCLCA2 strongly binds the beta 4 integrin (lane 1), but not anti-beta 4 antibody alone (lane 2).

Specificity of the beta 4 Integrin/hCLCA2 Adhesion-- The specificity of the beta 4 integrin/hCLCA2 adhesion was confirmed by adhesion blocking experiments involving antibodies directed against either of the interacting adhesion molecules. Dramatic adhesion inhibition was seen only for anti-hCLCA2 pAb 18 and anti-beta 4 mAb 3E1, while all other antibodies tested had no effect on the beta 4/hCLCA2 adhesion (Fig. 5, A and B). Neither of the two anti-hCLCA2 antibodies had any effect on the adhesion of MDA-MB-231 cells to human placenta-derived laminin used as a control substrate, while both anti-beta 4 antibodies 3E1 and 81435 inhibited laminin adhesion of MDA-MB-231 cells (Fig. 5, A and B). To exclude a possible participation of the alpha 6beta 1 integrin, expressed in all human breast cancer cell lines used in this study, in the hCLCA2 adhesion, functional anti-beta 1 antibodies (mAb 2253) were tested and found to be ineffective in blocking the adhesion between MDA-MB-231 cells and hCLCA2 but effective in blocking the adhesion to placenta laminin (Fig. 5C).


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 5.   Specificity of the beta 4 integrin/hCLCA2 adhesion. A-C, MDA-MB-231/hCLCA2 and MDA-MB-231/laminin adhesion inhibition experiments were done in microtitration plates coated with 3 µg/ml hCLCA2 or 7.5 µg/ml placental laminin, using anti-hCLCA2 antibodies (pAbs 4 and 18) (A), anti-beta 4 antibodies (3E1; 81435, 450-9D) and anti-alpha 6 antibodies (GoH3) (B), and functional anti-beta 1 antibodies (2253) (C). Anti-hCLCA2 pAb 18 and anti-beta 4 mAb 3E1 specifically block the adhesion of MDA-MB-231 to hCLCA2 but not anti-beta 1 mAb 2253. D, matrilysin treatment of MDA-MB-231 cells abolishes adhesion to hCLCA2 but not to placental laminin and causes degradation of the 205-kDa beta 4 integrin (Western blot, lane 2) but not the beta 1 integrin (Western blot, lane 4). Western lanes 1 and 3 are untreated controls. E, MDA-MB-231 cancer cells were labeled in phosphate-free DMEM containing H332PO4 at a final concentration of 0.5 mCi/ml for 4 h at 37 °C and then seeded onto BSA (10 µg/ml)-, fibronectin (5 µg/ml)-, hCLCA2 (3 µg/ml)-, placental laminin (7.5 µg/ml)-, and poly-L-lysine (1 mg/ml)-coated dishes, incubated for 20 min at 37 °C, and lysed. Lysates were immunoprecipitated with anti-beta 4 mAb 3E1, and precipitates were resolved by SDS-PAGE and treated with 1 M KOH for 2 h at 55 °C. Tyrosine-phosphorylated proteins are visualized by autoradiography. *, Student's t test; p < 0.01 (mean ± S.D. from four experiments).

In a second series of experiments, we show that selective cleavage of the beta 4 integrin ectodomain with matrilysin (30) totally abolishes MDA-MB-231 adhesion to hCLCA2 yet had a negligible effect on the adhesion to placental laminin (Fig. 5D). These adhesion data were supported by Western analyses showing specific cleavage of the 205-kDa beta 4 protein but not the beta 1 integrin in matrilysin-treated tumor cells. Finally, we examined whether the MDA-MB-231 beta 4 integrin was activated selectively when tumor cells were plated onto surfaces coated with hCLCA2 (Fig. 5E). Data showed prominent tyrosine phosphorylation of beta 4 integrin in tumor cells bound to hCLCA2 and to placental laminin (31, 32). In contrast, fibronectin generated only a weak tyrosine phosphorylation reaction, and BSA and poly-L-lysine had no effect (Fig. 5E).

Lung Metastasis Is Inhibited by beta 4/hCLCA2 Adhesion-blocking Antibodies-- To test whether the adhesion-inhibitory effects of anti-hCLCA2 and anti-beta 4 integrin antibodies extended to an inhibition of lung metastasis, we performed lung colony assays in nude mice with the lung metastatic breast cancer cell line MDA-MB-231 in the presence of these antibodies. Prior to conducting these assays, we established that human MDA-MB-231 cells were able to adhere to mCLCA1 (Table I), the mouse counterpart of hCLCA2, and that this adhesion was inhibited with anti-Lu-ECAM-1 mAb 6D3 (22) (cross-reacts with mCLCA1) and anti-beta 4 integrin mAb 3E1. Anti-beta 4 mAb 3E1 was preincubated for 30 min and injected together with tumor cells, while mAb 6D3 was injected with tumor cells without preincubation. Control experiments were conducted in the presence of nonimmune mouse IgG. Mice sacrificed 15 weeks later revealed that both antibodies effectively blocked the colonization of the lungs by MDA-MB-231 cells, causing an 84% inhibition of lung metastasis with mAb 6D3 and a 100% inhibition with mAb 3E1 relative to mIgG-treated controls (Table I).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Inhibition of lung colonization by the human breast cancer cell line MDA-MB-231 with anti-mCLCA1 and anti-beta 4 integrin antibodies

Effect of in Vivo Selection for Lung Metastatic Efficiency Versus beta 4 Integrin Transfection-- To test whether in vivo selection for increased lung metastatic performance was associated with increased beta 4 expression, we compared the alpha 6, beta 1, and beta 4 expression patterns of the selected cell line MDA-MB-435L2 (20) with those of the parental MDA-MB-435 cell line and the beta 4-transfected MDA-MB-435beta 4 cell line (24). The parental MDA-MB-435 cell line exhibited strong expression of the alpha 6 and beta 1 integrin subunits but only background levels of the beta 4 integrin. Accordingly, these tumor cells adhered strongly to both placental and EHS laminins but poorly to hCLCA2 (5 ± 3%; Fig. 6A). The selected MDA-MB-435L2 expressed comparable levels of the alpha 6 and beta 1 integrin subunits and a modest increase in surface expression of the beta 4 integrin. In accordance with this expression pattern, MDA-MB-435L2 cells adhered strongly to the two laminins and exhibited an increased adhesion to hCLCA2 (25 ± 3%; Fig. 6A). These data were contrasted with those from the parental MDA-MB-435 cell line that had been transfected with human beta 4 integrin and then selected for antibiotic resistance and by FACS for efficient stable expression of beta 4 (24). Transfectant cells expressed significantly higher levels of beta 4 integrin than MDA-MB-435L2 cells and adhered in higher numbers to hCLCA2 but in similar numbers to the two laminins, since the expression levels for both alpha 6 and beta 1 remained unchanged. Transfection of MDA-MB-435 cells with tailless beta 4 integrin (beta 4Delta cyt) underscored requirement of the "complete" beta 4 integrin subunit in hCLCA2 binding, since adhesion to hCLCA2 did not improve relative to that of parental cells (7 ± 3%; Fig. 6A), albeit the expression level of the truncated beta 4 was equal to that of wild-type beta 4 expression in MDA-MB-231 cells. Consistent with published data, adhesion of beta 4Delta cyt-transfected MDA-MB-435 cells to murine EHS laminin was also abolished (24), but not to human placental laminin (33).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of in vivo selection versus beta 4-transfection on hCLCA2 adhesion of human breast cancer cells. A, MDA-MB-231, MDA-MB-435, MDA-MB-435L2, MDA-MB-435beta 4, and MDA-MB-435beta 4Delta cyt were analyzed for alpha 6, beta 1, and beta 4 expression by FACS, and the expression patterns were contrasted with adhesion to hCLCA2 and EHS (bars 1) and placental (bars 2) laminins (coated at 3 µg/ml, 20 µg/ml, and 7.5 µg/ml, respectively). In vivo selection of MDA-MB-435 for enhanced lung colonization (MDA-MB-435L2) (20) and stable beta 4 transfection of MDA-MB-435 (MDA-MB-435beta 4) (24) increases beta 4 expression and adhesion to hCLCA2, while adhesion to the two laminins remains unchanged. Stable transfection of MDA-MB-435 with tailless beta 4 (MDA-MB-435beta 4Delta cyt) (24) increases beta 4 expression as detected with anti-beta 4 mAb 3E1 (directed against the extracellular domain of the beta 4 integrin), but beta 4Delta cyt-transfectants adhere in similarly poor numbers to hCLCA2 as parental cells. Adhesion of MDA-MB-435beta 4Delta cyt to EHS laminin (bar 1) is abolished, but not adhesion to placental laminin (bar 2). B, extracts from surface-biotinylated MDA-MB-231, MDA-MB-435beta 4, MDA-MB-435beta 4Delta cyt, and MDA-MB-435 cells were subjected to immunoprecipitation with anti-beta 4 pAb H101 (upper panel) or anti-alpha 6 mAb GoH3 (lower panel). Immunoprecipitates were resolved by SDS-PAGE (6%) and blotted to nitrocellulose and then probed with Streptavidin-HRP. Lane 1, MDA-MB-231; lane 2, MDA-MB-435beta 4; lane 3, MDA-MB-435; lane 4, MDA-MB-435beta 4Delta cyt.

As shown in Fig. 3, beta 4 cell surface expression and hCLCA2 adhesion correlated well with lung colonization of the established cell lines MDA-MB-231, MDA-MB-435L2, and MDA-MB-435. Median and range of the number of lung colonies were 30 (5-100), 5 (0-17), and 0 (0-3), respectively. To our surprise, however, the beta 4-transfected cell line MDA-MB-435beta 4 was unable to produce lung colonies following a 15-week incubation period in nude mice, although the parental cell line MDA-MB-435 is known to produce lung metastases after orthotopic tumor growth in mammary fat pads of nude mice and in vivo selection of these cells yielded a cell line with transiently enhanced lung colonization potential (MDA-MB-435L2) (20), which was lost gradually with increasing passage number. To explore whether differences in the quality of the beta 4 integrin expression on the surface of MDA-MB-231 and MDA-MB-435beta 4 cancer cells may have accounted for the discrepancy in the metastatic behavior, we examined the association between the beta 4 integrin and its presumed alpha 6 partner in the two cell lines. Surface-biotinylated cancer cells were first subjected to immunoprecipitation with anti-beta 4 pAb H101. As expected, the amounts of beta 4 detected in streptavidin-HRP-probed blots were comparable with that identified by FACS (Fig. 6, A and B). Next, the same tumor cell extracts were subjected to immunoprecipitation with anti-alpha 6 mAb GoH3, and precipitates were analyzed for beta 4-co-immunoprecipitation. Surprisingly, only the beta 4 of MDA-MB-231 cells was effectively co-precipitated with alpha 6, while negligible amounts of beta 4 were co-precipitated from MDA-MB-435beta 4 cells and none from MDA-MB-435 (Fig. 6B, lanes 1-3). Since beta 4Delta cyt is also effectively co-immunoprecipitated with alpha 6 from MDA-MB-435beta 4Delta cyt extracts (Fig. 6B, lane 4), our data imply that wild-type beta 4 transfected into MDA-MB-435 cells may interact with an intrinsic protein that affects co-immunoprecipitation with alpha 6 and metastasis but not in vitro adhesion to hCLCA2.

Transfection of Kirsten-Ras-transformed Balb/3T3 Cells with beta 4 Promotes Adhesion to hCLCA2 and Lung Colonization-- To determine whether overexpression of the beta 4 integrin in a cell line that expresses low levels of beta 4 integrin and, accordingly, has modest, yet consistent, lung metastatic capabilities, we chose a murine over a human tumor model. The former had the significant advantage that the metastatic performance could be tested in a syngeneic rather than a heterogeneic animal. Moreover, the induction time of generating macroscopically detectable lung colonies was only 3-4 weeks in syngeneic animals (13-15) versus a minimum of 15 weeks in a human/mouse model (20). The cell line we selected was the Kirsten-Ras-transformed Balb/3T3 cell line, which expressed low levels of the beta 4 integrin and consistently produced a moderate number of lung colonies upon tail vein injection. These tumor cells were transfected with beta 4 integrin cDNA or vector alone, and stable transfectants were selected based on antibiotic resistance. Expression of the beta 4 integrin was confirmed by FACS and surface biotinylation, both methods indicating a significantly increased surface expression of beta 4 integrin, which was co-immunoprecipitable with alpha 6, in beta 4-transfected relative to vector-transfected cells (Fig. 7A). Prior to conducting a lung colony assay, adhesion assays were performed with mCLCA1, the mouse counterpart of hCLCA2. Adhesion of beta 4-transfected K-Balb cells to mCLCA1 was 66 ± 5% relative to 9 ± 4% for mock-transfected K-Balb cells (Fig. 7B). These adhesion data paralleled the metastatic performance of the two cell lines. The beta 4-transfected K-Balb cells injected at 2 × 105 cells/mouse generated a median number of >100 colonies (69->100), while the mock-transfected cell line only generated 24 (15-29) lung colonies (Fig. 7B). This difference was also reflected in the average lung weights of the two experimental groups, measuring 0.71 ± 0.22 g in beta 4 transfectants and 0.45 ± 0.02 g in mock transfectants.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of stable beta 4 transfection of K-Balb/3T3 cells on mCLCA1 adhesion and lung colony formation. A, Kirsten-Ras-transformed Balb/3T3 (K-Balb/3T3) cells were transfected by electroporation with beta 4 integrin cDNA, and stable expressors were selected by G418 resistance. Wild-type K-Balb/3T3 cells (gray filled histogram), mock-transfected K-Balb/3T3 cells (thin open histogram), and beta 4-transfected K-Balb/3T3 cells (thick open histogram) were stained with rabbit anti-beta 4 pAb H101 and fluorescein isothiocyanate-conjugated goat anti-rabbit IgG secondary antibody and then analyzed by FACS. Inset, anti-beta 4 pAb H101 immunoprecipitates from extracts of surface-biotinylated beta 4-transfected K-Balb/3T3 cells (a, lane 1) and mock-transfected K-Balb/3T3 cells (a, lane 2) and anti-alpha 6 mAb GoH3 immunoprecipitates from surface-biotinylated, beta 4-transfected K-Balb/3T3 cells (b, lane 1). B, lung colony formation by beta 4-transfected K-Balb/3T3 cells. Balb/c mice (6-weeks old; male) were injected into the lateral tail vein with 2 × 105 tumor cells plus 0.3 ml of DMEM/mouse, and lung weights (g) and number of lung colonies were determined 3 weeks after tumor cell injection. Data were evaluated by Student's t test (unpaired data). *, p < 0.01 (relative to K-Balb-Mock).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this report, we describe a novel adhesion receptor/ligand pair that mediates colonization of the lungs by human breast cancer cells and possibly other cancer cell types. The pair consists of lung endothelial cell hCLCA2 and breast cancer cell beta 4 integrin. Human CLCA2 is expressed by endothelia lining arterial and venous branches, all presumably derived from the bronchial artery, while prominent expression of the beta 4 integrin has been associated with the invasive and metastatic phenotypes of breast cancer cells (24, 34-37). The location of MDA-MB-231 breast cancer metastases in mouse lungs is consistent with the vascular expression pattern of the mouse counterpart of hCLCA2 (mCLCA1) (10) as well as the recently established pattern of lung metastases by in situ epifluorescence microscopy (11). The binding interaction between the two lung metastasis-promoting adhesion molecules is documented by co-immunoprecipitation of the adhesion receptor/ligand pair from extracts of hCLCA2-transfected HEK293 monolayers to which MDA-MB-231 cells were bound, by hCLCA2 affinity chromatography, and by adhesion and metastasis inhibition experiments using functional antibodies. Participation of an "intermediary binding molecule" in the beta 4 integrin/hCLCA2 adhesion was excluded by Far Western analyses, using blotted immunopurified beta 4 or Myc-hCLCA2 and the corresponding purified adhesion partner as probe. Strong and specific binding between blotted beta 4 integrin and Myc-hCLCA2 indicated that the beta 4 integrin was able to recognize its endothelial cell receptor even after undergoing a vigorous denaturing/renaturing treatment, suggesting that the usually required interaction between alpha  and beta  integrin subunits (38, 39) and/or other interacting cell surface and intracellular molecules (40, 41) is not a mandate for the beta 4 integrin/hCLCA2 adhesion function in vitro. This behavior is similar to that recently reported for the beta 4 integrin/Shc adhesion, using blotted beta 4 integrin under denaturing/renaturing Far Western conditions (42).

Molecular cloning of hCLCA2 from a lung cDNA library and biochemical and functional characterization of hCLCA2 protein have shown that the molecule shares many of the characteristics of the other CLCA family members (18). The adhesion function of CLCA channel proteins is perplexing but not without precedent. Studies involving the cystic fibrosis transmembrane conductance regulator have shown that this chloride channel protein is also a cellular adhesion receptor for Pseudomonas aeruginosa (16) and Salmonella typhi (17). In cancer metastasis, a novel concept is the possible involvement of a CLCA-mediated Cl- conductance in cancer cell extravasation by induction of apoptosis in the endothelium of the target organ. Support for such involvement came from recent observations that breast cancer cells seeded atop a monolayer of hCLCA2-expressing HUVEC apparently induce apoptosis in apposed endothelial cells (43). Endothelial apoptosis appears to involve expression and activation of chloride channels (44, 45), leading to intracellular acidification and, in turn, activation of endonucleases and chromatin digestion (44). The advantage of a selective induction of apoptosis in those endothelial cells to which tumor cells are bound is obvious, since reduction of the endothelial cell by apoptotic vesiculation may create an avenue for invasion of perivascular tissues by tumor cells. The notion that these events are initiated by beta 4/hCLCA2 adhesion is supported by our preliminary observation that endothelial cells incubated with immunopurified beta 4 integrin rapidly undergo apoptosis. The apoptotic index of beta 4-treated endothelial cells was 26%, relative to 4% in untreated endothelial cells.2

The beta 4 integrin has previously been linked to metastatic disease (13, 46-49) and is confirmed here as a lung metastasis-associated gene in breast cancer. Consistent with the involvement of multiple genes in metastasis (1-8), the beta 4 integrin, like other metastasis-associated genes including MMP-2, CD44, alpha vbeta 3 integrin, and alpha 6 integrin (50), is by itself incapable of conferring mastery of the complex, multistep cascade of metastasis. This is exemplified by the MDA-MB-468 breast cancer cell line, which expresses the alpha 6beta 4 integrin at relatively high levels and, accordingly, is able to adhere to hCLCA2 in vitro but fails to produce metastases upon tail vein inoculation (Fig. 3). When this cell line is compared with a metastatically competent, beta 4-expressing cell line such as MDA-MB-231, the former expresses a phenotype that is comparable with the spontaneously immortalized, nontumorigenic beta 4 integrin-expressing breast epithelial cell line MFC-10A (51), while the latter expresses an aggressive, invasive, and metastatic phenotype (20). This difference is manifested by the formation of a contact-inhibited, cobblestone-like monolayer in vitro and adenomatous growth in vivo by MDA-MB-468 cells but anaplastic, crisscrossed, and multilayered growth in vitro and the formation of invasive and metastatic tumors in vivo by MDA-MB-231 cells (20). Genotype analyses indicate that the latter cell line expresses an array of gene abnormalities that have been associated with metastasis such as overexpression of c-erbB-2 (52), MTA1 (53, 54), MT1-MMP (55), vimentin (56), alpha 6 integrin (57), and VEGF (58) and down-regulation or loss of E-cadherin (59), nm23-H1 (60), and MUC1 (61), while most of these genes are expressed at normal or near normal levels in MDA-MB-468 cells (50, 53, 55, 56, 62). These data imply that beta 4 integrin expression leads to lung metastasis only in those cancer cells possessing a genotype that is otherwise compatible with metastasis. A similar scenario as described for the beta 4 integrin has also been reported for other metastasis-associated proteins including MMP-2, CD44, alpha vbeta 3 integrin, alpha 6 integrin, Rho GTPases, and fibronectin, which are prominently expressed in many highly invasive and metastatic tumor cells but individually are also detected in benign, nonmetastatic tumor cells and even normal cells (25, 63-67).

While an early stage of tumor progression (benign, well differentiated tumor) may have accounted for lack of metastasis in beta 4-expressing MDA-MB-468 cells, an altered modulation of the beta 4 integrin by lateral associations with other membrane (and/or cytoplasmic) proteins (reviewed in Refs. 40 and 41) in beta 4-transfected MDA-MB-435 cells versus MDA-MB-231 cells may have been responsible for the observed discrepancy in the metastatic behavior of the two cell lines. Although we have as yet no evidence of such a differential lateral association of the beta 4 integrin in the two cell lines, we show here that anti-alpha 6 antibodies fail to co-immunoprecipitate the beta 4 integrin from beta 4-transfected MDA-MB-435 cell extracts but effectively do so from MDA-MB-231 cell extracts (as well as from extracts of immortalized normal breast epithelial cells MCF-10A and benign breast tumor cells MDA-MB-468; data not shown). This differential partitioning of the beta 4 integrin in MDA-MB-231 and MDA-MB-435beta 4 cells, which incidentally express virtually identical amounts of alpha 6 and beta 1 integrins, and only a slightly reduced level of beta 4 in the MDA-MB-435beta 4 cell line is difficult to explain. However, it is possible that under our extraction conditions (1% Triton X-100), lateral association of the beta 4 integrin with an as yet undetermined membrane or cytoplasmic protein in beta 4-transfected MDA-MB-435 cells may have weakened the binding interaction between the alpha 6 and beta 4 integrin subunits, resulting not only in failure of the two integrin subunits to co-immunoprecipitate but also in inability to metastasize. Control co-immunoprecipitation of alpha 6 and beta 4Delta cyt suggests that such association is mediated by the cytoplasmic tail of the beta 4 integrin. Alternatively, our data may have been affected by the unlikely event that the beta 4 integrin subunit may associate with an as yet unidentified alpha  chain to permit cell surface expression in beta 4-transfected MDA-MB-435 tumor cells.

These considerations have important experimental consequences for metastasis research, since transfection of a gene suspected to play a primary role in metastasis into a tumor cell line that is nonmetastatic may not yield the expected result, since the introduced gene, even if it appropriately associates with other membrane proteins to achieve proper function, may not be sufficient in endowing tumors with mastery over the complete metastatic cascade. Therefore, we have relied in our transfection studies on a cell line that has a low lung metastatic potential and, thus, expresses a gene array that is conducive to lung metastasis including a low level of beta 4 integrin expression. When the beta 4 integrin is overexpressed in these cells, the number of lung colonies generated from intravenously injected tumor cells increases proportional to the level of alpha 6 co-immunoprecipitable beta 4 integrin. Consistent with involvement of the beta 4 integrin gene in metastasis, blockage of the beta 4/hCLCA2 adhesion abrogates metastasis. Similar effects are achieved by blocking other metastasis-associated genes each facilitating a different step in the metastatic cascade, e.g. RhoC, metalloproteinases, heparatinase, angiogenic factors, dipeptidyl peptidase IV (68-75).

In conclusion, we have provided molecular evidence in support of the observed link between beta 4 expression and malignant progression (reviewed in Ref. 21), ascribing a key role to the adhesion mechanism between beta 4 integrin and vascular endothelial cell hCLCA2 in lung metastasis. Although only a few examples of integrin involvement in cell-to-cell adhesion are known (e.g. leukocyte integrins alpha Lbeta 2 and alpha Mbeta 2 bind to endothelial cell ICAM-1, integrins alpha 4beta 1 and alpha 7beta 1 to VCAM-1, and alpha Ebeta 7 to E-cadherin (reviewed in Ref. 39)), we have identified and cloned for the first time a beta 4 integrin-binding protein that is an integral membrane protein and that is entirely new as an integrin-binding partner (15, 18). Our discovery that hCLCA2 has an important function in heterotypic cell-to-cell adhesion in addition to that in Ca2+-sensitive chloride conductance extends the basic knowledge about this protein and indicates that ion channels can have multiple, seemingly unrelated functions (16-18, 44, 76).

    ACKNOWLEDGEMENT

We thank Dr. Renée A. Christopher for involvement in the preparation of the manuscript and Heather Archibald and the staff of the Image Lab for expert technical assistance.

    FOOTNOTES

* This work was supported by NCI, National Institutes of Health, Public Health Service Grants CA47668 and CA71626 (to B. U. P.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Cancer Biology Laboratories, Dept. of Molecular Medicine, Cornell University College of Veterinary Medicine, Ithaca, New York 14853. Tel.: 607-253-3343; Fax: 607-253-3708; E-mail: bup1@cornell.edu.

Published, JBC Papers in Press, April 24, 2001, DOI 10.1074/jbc.M100478200

2 B. U. Pauli, H.-C. Cheng, and M. Abdel-Ghany, manuscript in preparation.

    ABBREVIATIONS

The abbreviations used are: hCLCA2, human CLCA2; mCLCA1, mouse CLCA1; mAb, monoclonal antibody; pAb, polyclonal antibody; HMVEC-L, human lung microvascular endothelial cells; HAEC, human aortic endothelial cells; HUVEC, human umbilical vein endothelial cells; HEK, human embryonic kidney; RT, reverse transcriptase; PCR, polymerase chain reaction; PAGE, polyacrylamide gel electrophoresis; BSA, bovine serum albumin; HRP, horseradish peroxidase; FACS, fluorescence-activated cell sorting; DMEM, Dulbecco's modified Eagle's medium.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Zhang, L., Zhou, W., Velculescu, V. E., Kern, S. E., Hruban, R. H., Hamilton, S. R., Vogelstein, B., and Kinzler, K. W. (1997) Science 276, 1268-1272[Abstract/Free Full Text]
2. Perou, C. M., Sorlie, T., Eisen, M. B., van de, R. M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., Fluge, O., Pergamenschikov, A., Williams, C., Zhu, S. X., Lonning, P. E., Borresen-Dale, A. L., Brown, P. O., and Botstein, D. (2000) Nature 406, 747-752[CrossRef][Medline] [Order article via Infotrieve]
3. Hanahan, D., and Weinberg, R. A. (2000) Cell 100, 57-70[Medline] [Order article via Infotrieve]
4. Fidler, I. J. (2000) Cancer J. Sci. Am. 6 Suppl. 2, 134-141
5. Shain, K. H., Landowski, T. H., and Dalton, W. S. (2000) Curr. Opin. Oncol. 12, 557-563[CrossRef][Medline] [Order article via Infotrieve]
6. Zetter, B. R. (1993) Semin. Cancer Biol. 4, 219-229[Medline] [Order article via Infotrieve]
7. Pauli, B. U., and Lin, H. (1997) in Encyclopedia of Cancer (Bertino, J. R., ed), Vol. 1 , pp. 464-476, Academic Press, Inc., San Diego
8. Orr, F. W., Wang, H. H., Lafrenie, R. M., Scherbarth, S., and Nance, D. M. (2000) J. Pathol. 190, 310-329[CrossRef][Medline] [Order article via Infotrieve]
9. Goetz, D. J., el Sabban, M. E., Hammer, D. A., and Pauli, B. U. (1996) Int. J. Cancer 65, 192-199[CrossRef][Medline] [Order article via Infotrieve]
10. Zhu, D., and Pauli, B. U. (1993) Int. J. Cancer 53, 628-633[Medline] [Order article via Infotrieve]
11. Al Mehdi, A. B., Tozawa, K., Fisher, A. B., Shientag, L., Lee, A., and Muschel, R. J. (2000) Nat. Med. 6, 100-102[CrossRef][Medline] [Order article via Infotrieve]
12. Pauli, B. U., and Lee, C. L. (1988) Lab. Invest. 58, 379-387[Medline] [Order article via Infotrieve]
13. Zhu, D. Z., Cheng, C. F., and Pauli, B. U. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 9568-9572[Abstract]
14. Zhu, D., Cheng, C. F., and Pauli, B. U. (1992) J. Clin. Invest. 89, 1718-1724[Medline] [Order article via Infotrieve]
15. Elble, R. C., Widom, J., Gruber, A. D., Abdel-Ghany, M., Levine, R., Goodwin, A., Cheng, H. C., and Pauli, B. U. (1997) J. Biol. Chem. 272, 27853-27861[Abstract/Free Full Text]
16. Pier, G. B., Grout, M., and Zaidi, T. S. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 12088-12093[Abstract/Free Full Text]
17. Pier, G. B., Grout, M., Zaidi, T., Meluleni, G., Mueschenborn, S. S., Banting, G., Ratcliff, R., Evans, M. J., and Colledge, W. H. (1998) Nature 393, 79-82[CrossRef][Medline] [Order article via Infotrieve]
18. Pauli, B. U., Abdel-Ghany, M., Cheng, H. C., Gruber, A. D., Archibald, H. A., and Elble, R. C. (2000) Clin. Exp. Pharmacol. Physiol. 27, 901-905[CrossRef][Medline] [Order article via Infotrieve]
19. Gruber, A. D., Schreur, K. D., Ji, H. L., Fuller, C. M., and Pauli, B. U. (1999) Am. J. Physiol. 276, C1261-C1270[Medline] [Order article via Infotrieve]
20. Price, J. E. (1996) Breast Cancer Res. Treat. 39, 93-102[Medline] [Order article via Infotrieve]
21. Rabinovitz, I., and Mercurio, A. M. (1996) Biochem. Cell Biol. 74, 811-821[Medline] [Order article via Infotrieve]
22. Zhu, D. Z., and Pauli, B. U. (1991) J. Histochem. Cytochem. 39, 1137-1142[Abstract]
23. Kemperman, H., Wijnands, Y., de Rijk, D., and Roos, E. (1993) Cancer Res. 53, 3611-3617[Abstract]
24. Shaw, L. M., Chao, C., Wewer, U. M., and Mercurio, A. M. (1996) Cancer Res. 56, 959-963[Abstract]
25. Cheng, H. C., Abdel-Ghany, M., Elble, R. C., and Pauli, B. U. (1998) J. Biol. Chem. 273, 24207-24215[Abstract/Free Full Text]
26. Giancotti, F. G., Stepp, M. A., Suzuki, S., Engvall, E., and Ruoslahti, E. (1992) J. Cell Biol. 118, 951-959[Abstract]
27. Potts, A. J., Croall, D. E., and Hemler, M. E. (1994) Exp. Cell Res. 212, 2-9[CrossRef][Medline] [Order article via Infotrieve]
28. Abdel-Ghany, M., Kole, H. K., and Racker, E. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 8888-8892[Abstract]
29. Aguirre, K. M., McCormick, R. J., and Schwarzbauer, J. E. (1994) J. Biol. Chem. 269, 27863-27868[Abstract/Free Full Text]
30. von Bredow, D. C., Nagle, R. B., Bowden, G. T., and Cress, A. E. (1997) Exp. Cell Res. 236, 341-345[CrossRef][Medline] [Order article via Infotrieve]
31. Mainiero, F., Pepe, A., Wary, K. K., Spinardi, L., Mohammadi, M., Schlessinger, J., and Giancotti, F. G. (1995) EMBO J. 14, 4470-4481[Abstract]
32. Mainiero, F., Pepe, A., Yeon, M., Ren, Y., and Giancotti, F. G. (1996) J. Cell Biol. 134, 241-253[Abstract]
33. Spinardi, L., Einheber, S., Cullen, T., Milner, T. A., and Giancotti, F. G. (1995) J. Cell Biol. 129, 473-487[Abstract]
34. Jones, J. L., Royall, J. E., Critchley, D. R., and Walker, R. A. (1997) Exp. Cell Res. 235, 325-333[CrossRef][Medline] [Order article via Infotrieve]
35. Falcioni, R., Antonini, A., Nistico, P., Di Stefano, S., Crescenzi, M., Natali, P. G., and Sacchi, A. (1997) Exp. Cell Res. 236, 76-85[CrossRef][Medline] [Order article via Infotrieve]
36. O'Connor, K. L., Shaw, L. M., and Mercurio, A. M. (1998) J. Cell Biol. 143, 1749-1760[Abstract/Free Full Text]
37. Gambaletta, D., Marchetti, A., Benedetti, L., Mercurio, A. M., Sacchi, A., and Falcioni, R. (2000) J. Biol. Chem. 275, 10604-10610[Abstract/Free Full Text]
38. Loftus, J. C., and Liddington, R. C. (1997) J. Clin. Invest. 99, 2302-2306[Free Full Text]
39. Plow, E. F., Haas, T. A., Zhang, L., Loftus, J., and Smith, J. W. (2000) J. Biol. Chem. 275, 21785-21788[Free Full Text]
40. Hemler, M. E. (1998) Curr. Opin. Cell Biol. 10, 578-585[CrossRef][Medline] [Order article via Infotrieve]
41. Woods, A., and Couchman, J. R. (2000) J. Biol. Chem. 275, 24233-24236[Free Full Text]
42. Dans, M., Gagnoux-Palacios, L., Blaikie, P., Klein, S., Mariotti, A., and Giancotti, F. G. (2001) J. Biol. Chem. 276, 1494-1502[Abstract/Free Full Text]
43. Kebers, F., Lewalle, J. M., Desreux, J., Munaut, C., Devy, L., Foidart, J. M., and Noel, A. (1998) Exp. Cell Res. 240, 197-205[CrossRef][Medline] [Order article via Infotrieve]
44. Szabo, I., Lepple-Wienhues, A., Kaba, K. N., Zoratti, M., Gulbins, E., and Lang, F. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 6169-6174[Abstract/Free Full Text]
45. Gottlieb, R. A., and Dosanjh, A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 3587-3591[Abstract/Free Full Text]
46. Falcioni, R., Kennel, S. J., Giacomini, P., Zupi, G., and Sacchi, A. (1986) Cancer Res. 46, 5772-5778[Abstract]
47. Perrotti, D., Cimino, L., Falcioni, R., Tibursi, G., Gentileschi, M. P., and Sacchi, A. (1990) Anticancer Res. 10, 1587-1597[Medline] [Order article via Infotrieve]
48. Rossen, K., Dahlstrom, K. K., Mercurio, A. M., and Wewer, U. M. (1994) Acta Dermato-Venereologica 74, 101-105[Medline] [Order article via Infotrieve]
49. Cimino, L., Perrotti, D., D'Agostino, G., Falcioni, R., and Sacchi, A. (1997) Cancer Detect. Prev. 21, 158-166[Medline] [Order article via Infotrieve]
50. Roetger, A., Merschjann, A., Dittmar, T., Jackisch, C., Barnekow, A., and Brandt, B. (1998) Am. J. Pathol. 153, 1797-1806[Abstract/Free Full Text]
51. Soule, H. D., Maloney, T. M., Wolman, S. R., Peterson, W. D., Brenz, R., McGrath, C. M., Russo, J., Pauley, R. J., Jones, R. F., and Brooks, S. C. (1990) Cancer Res. 50, 6075-6086[Abstract]
52. Lee-Huang, S., Huang, P. L., Sun, Y., Chen, H. C., Kung, H. F., Huang, P. L., and Murphy, W. J. (2000) Anticancer Res. 20, 653-659[Medline] [Order article via Infotrieve]
53. Toh, Y., Pencil, S. D., and Nicolson, G. L. (1995) Gene (Amst.) 159, 97-104[CrossRef][Medline] [Order article via Infotrieve]
54. Nawa, A., Nishimori, K., Lin, P., Maki, Y., Moue, K., Sawada, H., Toh, Y., Fumitaka, K., and Nicolson, G. L. (2000) J. Cell. Biochem. 79, 202-212[CrossRef][Medline] [Order article via Infotrieve]
55. Pulyaeva, H., Bueno, J., Polette, M., Birembaut, P., Sato, H., Seiki, M., and Thompson, E. W. (1997) Clin. Exp. Metastasis 15, 111-120[CrossRef][Medline] [Order article via Infotrieve]
56. Thompson, E. W., Paik, S., Brunner, N., Sommers, C. L., Zugmaier, G., Clarke, R., Shima, T. B., Torri, J., Donahue, S., Lippman, M. E., Martin, G. R., and Dickson, R. B. (1992) J. Cell. Physiol. 150, 534-544[Medline] [Order article via Infotrieve]
57. Mukhopadhyay, R., Theriault, R. L., and Price, J. E. (1999) Clin. Exp. Metastasis 17, 325-332[Medline] [Order article via Infotrieve]
58. Donovan, D., Harmey, J. H., Toomey, D., Osborne, D. H., Redmond, H. P., and Bouchier-Hayes, D. J. (1997) Ann. Surg. Oncol. 4, 621-627[Abstract]
59. Mbalaviele, G., Dunstan, C. R., Sasaki, A., Williams, P. J., Mundy, G. R., and Yoneda, T. (1996) Cancer Res. 56, 4063-4070[Abstract]
60. Russell, R. L., Geisinger, K. R., Mehta, R. R., White, W. L., Shelton, B., and Kute, T. E. (1997) Cancer 79, 1158-1165[CrossRef][Medline] [Order article via Infotrieve]
61. Walsh, M. D., Luckie, S. M., Cummings, M. C., Antalis, T. M., and McGuckin, M. A. (1999) Breast Cancer Res. Treat. 58, 255-266[Medline] [Order article via Infotrieve]
62. Hazan, R. B., and Norton, L. (1998) J. Biol. Chem. 273, 9078-9084[Abstract/Free Full Text]
63. Bohm, J. P., Niskanen, L. K., Pirinen, R. T., Kiraly, K., Kellokoski, J. K., Moisio, K. I., Eskelinen, M. J., Tulla, H. E., Hollmen, S., Alhava, E. M., and Kosma, V. M. (2000) J. Pathol. 192, 321-327[CrossRef][Medline] [Order article via Infotrieve]
64. Fritz, G., Just, I., and Kaina, B. (1999) Int. J. Cancer 81, 682-687[CrossRef][Medline] [Order article via Infotrieve]
65. Hofmann, U. B., Westphal, J. R., van Muijen, G. N., and Ruiter, D. J. (2000) J. Invest. Dermatol. 115, 337-344[Abstract/Free Full Text]
66. Maguire, P. D., Qi, W., Lallemand, R., and Scully, S. P. (2000) Oncology 59, 139-144[CrossRef][Medline] [Order article via Infotrieve]
67. Taverna, D., Ullman-Cullere, M., Rayburn, H., Bronson, R. T., and Hynes, R. O. (1998) Cancer Res. 58, 848-853[Abstract]
68. Clark, E. A., Golub, T. R., Lander, E. S., and Hynes, R. O. (2000) Nature 406, 532-535[CrossRef][Medline] [Order article via Infotrieve]
69. Curran, S., and Murray, G. I. (2000) Eur. J. Cancer 36, 1621-1630[CrossRef][Medline] [Order article via Infotrieve]
70. Hulett, M. D., Freeman, C., Hamdorf, B. J., Baker, R. T., Harris, M. J., and Parish, C. R. (1999) Nat. Med. 5, 803-809[CrossRef][Medline] [Order article via Infotrieve]
71. Vlodavsky, I., Friedmann, Y., Elkin, M., Aingorn, H., Atzmon, R., Ishai-Michaeli, R., Bitan, M., Pappo, O., Peretz, T., Michal, I., Spector, L., and Pecker, I. (1999) Nat. Med. 5, 793-802[CrossRef][Medline] [Order article via Infotrieve]
72. Bergers, G., Javaherian, K., Lo, K. M., Folkman, J., and Hanahan, D. (1999) Science 284, 808-812[Abstract/Free Full Text]
73. Yip, D., Ahmad, A., Karapetis, C. S., Hawkins, C. A., and Harper, P. G. (1999) Invest. New Drugs 17, 387-399[CrossRef][Medline] [Order article via Infotrieve]
74. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. (1994) Cell 79, 315-328[Medline] [Order article via Infotrieve]
75. Abdel-Ghany, M., Cheng, H., Levine, R. A., and Pauli, B. U. (1998) Invasion Metastasis 18, 35-43[Medline] [Order article via Infotrieve]
76. Martin, D. K., Boneham, G. C., Pirie, B. L., Collin, H. B., and Campbell, T. J. (1996) Microvasc. Res. 52, 200-209[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.